Literature DB >> 33884212

Effects of Fenoldopam in the Pediatric Population: Fluid Status, Serum Biomarkers, and Hemodynamics: A Systematic Review and Meta-Analysis.

Enrique G Villarreal1,2, Jacqueline Rausa3, A Claire Chapel1, Rohit S Loomba3,4, Saul Flores1.   

Abstract

Fluid overload is a frequent complication in children during critical illness. Fluid restriction and diuretic agents have been the mainstay therapies so far. Fenoldopam, a selective dopamine-1 receptor agonist, is a diuretic agent with promising effects in the pediatric population. The purpose of this meta-analysis is to evaluate the outcomes of pediatric patients who received fenoldopam. We hypothesized that the administration of fenoldopam will cause an increase in urine output and decrease in serum creatinine in this patient population. A comprehensive database search of PubMed, EMBASE, and Cochrane libraries from the databases' inception through December 2018 was undertaken. Independent reviewers selected appropriate studies and the reviewed data. A meta-analysis was then conducted to determine the effects of fenoldopam on hemodynamics, the amount of vasoactive support, and renal function in children under the critical care setting. The selected end points were measured prior to the administration of fenoldopam and 24 hours after the initiation of the infusion: urine output, serum creatinine, serum sodium, inotrope score, heart rate, central venous pressure, systolic blood pressure, and mean blood pressure. Forest plots were generated to demonstrate individual study data as well as pooled data for each end point. A total of five studies (three retrospective cohort studies, two randomized trials) with 121 patients were included for analysis. No significant difference was observed in urine output, inotrope score, systolic blood pressure, or mean blood pressure. There was a statistically significant increase in serum creatinine and central venous pressure. There was statistically significant decrease in serum sodium and heart rate, and central venous pressure. This meta-analysis did not identify significant renoprotective or vasodilator effects from fenoldopam in this patient population. Although mild electrolyte and hemodynamic changes were identified, larger studies are warranted to determine the clinical significance of fenoldopam in this patient population. Thieme. All rights reserved.

Entities:  

Keywords:  critical care; fenoldopam; hemodynamics; pediatrics

Year:  2020        PMID: 33884212      PMCID: PMC8052110          DOI: 10.1055/s-0040-1714704

Source DB:  PubMed          Journal:  J Pediatr Intensive Care        ISSN: 2146-4626


  17 in total

Review 1.  Fenoldopam: a selective peripheral dopamine-receptor agonist for the treatment of severe hypertension.

Authors:  M B Murphy; C Murray; G D Shorten
Journal:  N Engl J Med       Date:  2001-11-22       Impact factor: 91.245

2.  The Renin-Angiotensin and Renal Dopaminergic Systems Interact in Normotensive Humans.

Authors:  Aruna R Natarajan; Gilbert M Eisner; Ines Armando; Shaunagh Browning; John C Pezzullo; Lauren Rhee; Mustafa Dajani; Robert M Carey; Pedro A Jose
Journal:  J Am Soc Nephrol       Date:  2015-05-14       Impact factor: 10.121

3.  The effects of fenoldopam, a selective dopamine receptor agonist, on systemic and renal hemodynamics in normotensive subjects.

Authors:  V S Mathur; S K Swan; L J Lambrecht; S Anjum; J Fellmann; D McGuire; M Epstein; R R Luther
Journal:  Crit Care Med       Date:  1999-09       Impact factor: 7.598

4.  Effect of laboratory testing guidelines on the utilization of tests and order entries in a surgical intensive care unit.

Authors:  Kanya Kumwilaisak; Alberto Noto; Ulrich H Schmidt; Clare I Beck; Claudia Crimi; Kent Lewandrowski; Luca M Bigatello
Journal:  Crit Care Med       Date:  2008-11       Impact factor: 7.598

5.  Diuretics, mortality, and nonrecovery of renal function in acute renal failure.

Authors:  Ravindra L Mehta; Maria T Pascual; Sharon Soroko; Glenn M Chertow
Journal:  JAMA       Date:  2002-11-27       Impact factor: 56.272

6.  An evaluation of off-label fenoldopam use in the neonatal intensive care unit.

Authors:  Sarah E Yoder; Bradley A Yoder
Journal:  Am J Perinatol       Date:  2009-05-18       Impact factor: 1.862

7.  Renal effects of fenoldopam in critically ill pediatric patients: A retrospective review.

Authors:  Brady S Moffett; Antonio R Mott; David P Nelson; Stuart L Goldstein; John Lynn Jefferies
Journal:  Pediatr Crit Care Med       Date:  2008-07       Impact factor: 3.624

8.  Pharmacokinetic and pharmacodynamic properties of intravenous fenoldopam, a dopamine1-receptor agonist, in hypertensive patients.

Authors:  R R Weber; C E McCoy; J A Ziemniak; E D Frederickson; L I Goldberg; M B Murphy
Journal:  Br J Clin Pharmacol       Date:  1988-01       Impact factor: 4.335

9.  Augmentation of renal blood flow and sodium excretion in hypertensive patients during blood pressure reduction by intravenous administration of the dopamine1 agonist fenoldopam.

Authors:  M B Murphy; C E McCoy; R R Weber; E D Frederickson; F L Douglas; L I Goldberg
Journal:  Circulation       Date:  1987-12       Impact factor: 29.690

10.  High-dose fenoldopam reduces postoperative neutrophil gelatinase-associated lipocaline and cystatin C levels in pediatric cardiac surgery.

Authors:  Zaccaria Ricci; Rosa Luciano; Isabella Favia; Cristiana Garisto; Maurizio Muraca; Stefano Morelli; Luca Di Chiara; Paola Cogo; Sergio Picardo
Journal:  Crit Care       Date:  2011-06-29       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.